Image Credit: Javier Zayas Photography/Getty Images 
In a medical experiment conducted between 2009 to 2013, a clinical trial tied to Tony Fauci tested the new technology of a messenger ribonucleic acid (mRNA) gene therapy-based ‘vaccine’ for the human immunodeficiency virus (HIV).
While this new technology proved to not be efficacious, it also did not cause any reported deaths or side effects, according to the study, although serious long-term data on the participants had not been compiled.
Of interest thirteen years later is the fact that mRNA so-called vaccines have only recently been rolled out to the public at large for the Communist Chinese Party (CCP) Virus – a virus engineered by a bioweapons lab in Wuhan to have the HIV delivery system grafted onto a cold virus.
Many of those who’ve been injected with the CCP Virus gene therapy ‘vaccine’ technology are now not only experiencing the symptoms of autoimmune deficiency syndrome (AIDS) but actually testing positive for HIV – the virus that is widely believed to cause AIDS.
This early HIV mRNA ‘vaccine’ study is sponsored by Tony Fauci’s National Institute of Allergy and Infectious Diseases (NIAID) and the National Institutes of Health (NIH).
Fauci was at the forefront of AIDS response in the 1980s, pushing deadly drugs like azidothymidine (AZT) on the infected populations. Later, Fauci headed up the heavy handed response to the CCP Virus, characterized by house arrest style quarantines referred to as lockdowns and corporate forced inoculation programs.
One of the notable reasons listed for interest in this study is that mRNA vaccines can be produced (once finally engineered) for much cheaper and assumably quicker than other more traditional methods.
“Transfection of mRNA encoding whole HIV-1 gene products also obviates the need to synthesize, purify, and characterize vaccine-grade protein immunogens, which is technically and financially challenging,” the study reported.
In the 2009 experiment, an mRNA-transfected autologous dendritic cell based ‘vaccine’ was used on HIV positive patients. Fifteen total subjects were used in this study, ten getting the mRNA-transfected autologous dendritic cell vaccine and five getting the autologous dendritic cells without transfected mRNA – a placebo of sorts, as the study seems to be focused on the mRNA technology.
In the end, the clinical trial concluded that this early HIV mRNA ‘vaccine’ attempt did not result in an efficacious and long lasting gene therapy, but did however indicate future methods which may net a more desirable result.
“Immunization with DCs transfected with mRNA encoding HIV-1 Gag and Nef did not induce significant interferon-gamma enzyme-linked immunospot responses. There were increases in proliferative responses to HIV-1 antigens and to a neo-antigen, KLH, but the effects were transient. Dendritic cell vaccination should be optimized to elicit stronger and long-lasting immune responses for this strategy to be effective as an HIV-1 therapeutic vaccine,” the study reported.
VAIDS: Vaccine Acquired Immunodeficiency Syndrome Infecting Vaxxed Worldwide